AstraZeneca has announced that it will be expanding its ongoing collaboration with Myriad Genetics to include a new companion diagnostics agreement.
The firm will be using Myriad Genetics' myChoice HRD Plus testing system in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza and Avastin.
“AstraZeneca is partnering with Myriad Genetics to identify women with advanced ovarian cancer who may benefit from a specific form of treatment.“
Under the terms of the deal, myChoice HRD Plus will be used to evaluate patients enrolled in an ongoing phase III trial, with the specific aim of identifying cases with homologous recombination deficiencies.
Myriad Genetics' test offers a comprehensive solution for detecting tumours that have lost the ability to repair double-stranded DNA breaks, meaning they are unusually susceptible to DNA-damaging therapies such as platinum drugs or PARP inhibitors.
Dr Jerry Lanchbury, chief scientific officer for Myriad Genetics, said: "We are excited to continue our collaboration with AstraZeneca and to apply innovative new technologies like myChoice HRD Plus to increase the number of patients who may benefit from Lynparza."
AstraZeneca and Myriad Genetics have been working together to create novel companion diagnostic tests since 2007.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical